Reasons why patients with hepatitis B are not recommended to use tenofovir alafenamide tablets (Vemlidy)

Tenofovir alafenamide fumarate tablets (Vemlidy) is a new type of nucleotide reverse transcriptase inhibitor (NRTI), mainly used to treat adult patients with chronic hepatitis B virus (HBV) infection. It reduces liver inflammation and fibrosis risk by inhibiting hepatitis B virus replication and reducing viral load in the blood. VemlidyIt is recommended for patients with mild to moderate renal insufficiency due to its high renal safety profile.

Although Vemlidy is mainly used for HBV infection, some patients with hepatitis B, especially those with severe liver function abnormalities or decompensated cirrhosis, are not recommended to use this drug. The reason is that drugs may increase the burden on liver function during liver metabolism and excretion. If the patient's liver function is unstable, the risk of drug-induced liver injury may increase.

VemlidyIt needs to be hydrolyzed into active ingredients by liver esterase in the body. Patients with liver dysfunction may cause the blood concentration of the drug to increase abnormally, thereby increasing the probability of adverse reactions, including lactic acidosis, abnormal renal function, and decreased bone mass. In addition, if hepatitis B patients are accompanied by acute hepatitis or virus rebound, using Vemlidy may not be able to effectively control virus replication, or even worsen the condition.

For patients with hepatitis B, liver function and viral status should be evaluated in detail before using Vemlidy. Patients with severe hepatic insufficiency or decompensated cirrhosis should give priority to other anti-hepatitis B drugs. During treatment, serum aminotransferases, liver function and viral load need to be monitored regularly to detect abnormalities in a timely manner and adjust the plan. At the same time, patients should avoid increasing or decreasing doses or discontinuing medication on their own to reduce liver risks and ensure efficacy.

Reference link:https://www.drugs.com